Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a new laser erase acne scars without harming darker skin?

NCT ID NCT05362929

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This trial tests whether a hybrid fractional laser can safely and effectively reduce acne scars in people with skin of color. About 50 adults with acne scarring will receive the laser treatment and be followed for nine months. Researchers will measure changes in scar severity, patient satisfaction, and any side effects like hyperpigmentation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sciton hybrid fractional laser treatment
What this could lead to
If effective, this laser could offer a safe, tailored option for reducing acne scars in people with darker skin tones, where traditional lasers carry higher risks of pigmentation changes.
What could go wrong
This is a small, early-stage study, and results may not apply to everyone. The laser could cause temporary redness, pain, or unwanted changes in skin color, especially in darker skin.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy males and females, ≥ 18 years of age at time of informed consent, seeking treatment for acne scarring * Subject must voluntarily sign and date an IRB approved informed consent form * Subjects with diagnosis of acne scarring recorded over the past 6 months * Able to read, understand and voluntarily provide written informed consent. * Subject is determined to be healthy, non-smoker * Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements. * Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period. Exclusion Criteria: * Subjects does not have the capacity to consent to the study * Subject underwent any acne scar treatments in the past 6 months prior to enrollment in the study * Subject has active papulopustular or cystic acne within the past 6 months * Any history of keloidal scarring * Any previous surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months * History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection), and/or any history of systemic chemotherapy for prior 12 months * Subject has no health contraindications to receiving local lidocaine and epinephrine injections, including but not limited to any form of heart disease or arrhythmia, untreated or uncontrolled severe hypertension, uncontrolled hyperthyroidism, uncontrolled diabetes, pheochromocytoma, cocaine use * History or current use of the following prescription medications: Immunosuppressive medications/biologics, 6 months prior to and during the study. Accutane or other systemic retinoids within the past twelve months TCA, MAO, or beta-blockers * Smoking or vaping in the past 12 months * History of photosensitivity and/or connective tissue disease * History of hyperlipidemia, diabetes mellitus, hepatitis, or bleeding disorders * History of major depressive disorders or endocrine disorders including but not limited to; hypothyroidism, Hashimoto's thyroiditis, or hyperthyroidism * History of ongoing pregnancy, active breastfeeding, cancer, and epilepsy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne scars - mixed atrophic and hypertrophic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperpigmentation hyperpigmentation of the skin Hypertrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 555 Taxter Road

    RECRUITING

    Elmsford, New York, 10523, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.